1 Finucane, M. M. et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet377, 557-567, doi:10.1016/S0140-6736(10)62037-5 (2011).
2 Swinburn, B. A. et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet378, 804-814, doi:10.1016/S0140-6736(11)60813-1 (2011).
3 Ng, M. et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet384, 766-781, doi:10.1016/S0140-6736(14)60460-8 (2014).
4 Olshansky, S. J. et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med352, 1138-1145, doi:10.1056/NEJMsr043743 (2005).
5 Lauby-Secretan, B. et al. Body Fatness and Cancer--Viewpoint of the IARC Working Group. N Engl J Med375, 794-798, doi:10.1056/NEJMsr1606602 (2016).
6 Heymsfield, S. B. & Wadden, T. A. Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med376, 1492, doi:10.1056/NEJMc1701944 (2017).
7 Yanovski, S. Z. & Yanovski, J. A. Long-term drug treatment for obesity: a systematic and clinical review. JAMA311, 74-86, doi:10.1001/jama.2013.281361 (2014).
8 Apovian, C. M. et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab100, 342-362, doi:10.1210/jc.2014-3415 (2015).
9 Davidson, M. H. et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA281, 235-242, doi:10.1001/jama.281.3.235 (1999).
10 Pi-Sunyer, X. et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med373, 11-22, doi:10.1056/NEJMoa1411892 (2015).
11 Smith, S. R. et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med363, 245-256, doi:10.1056/NEJMoa0909809 (2010).
12 Gadde, K. M. et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet377, 1341-1352, doi:10.1016/S0140-6736(11)60205-5 (2011).
13 Apovian, C. M. et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring)21, 935-943, doi:10.1002/oby.20309 (2013).
14 Zeng, B. B. et al. Studies on mimicry of naturally occurring annonaceous acetogenins: non-THF analogues leading to remarkable selective cytotoxicity against human tumor cells. Chemistry9, 282-290, doi:10.1002/chem.200390021 (2003).
15 Han, B. et al. Annonaceous acetogenin mimic AA005 suppresses human colon cancer cell growth in vivo through downregulation of Mcl-1. Acta Pharmacol Sin40, 231-242, doi:10.1038/s41401-018-0025-7 (2019).
16 Han, B. et al. Annonaceous acetogenin mimic AA005 induces cancer cell death via apoptosis inducing factor through a caspase-3-independent mechanism. BMC Cancer15, 139, doi:10.1186/s12885-015-1133-0 (2015).
17 Liu, H. X., Huang, G. R., Zhang, H. M., Wu, J. R. & Yao, Z. J. Annonaceous acetogenin mimics bearing a terminal lactam and their cytotoxicity against cancer cells. Bioorg Med Chem Lett17, 3426-3430, doi:10.1016/j.bmcl.2007.03.084 (2007).
18 Jiang, S. et al. Parallel fragment assembly strategy towards multiple-ether mimicry of anticancer annonaceous acetogenins. Angew Chem Int Ed Engl43, 329-334, doi:10.1002/anie.200352681 (2004).
19 Huang, G. R. et al. Induction of cell death of gastric cancer cells by a modified compound of the annonaceous acetogenin family. Chembiochem4, 1216-1221, doi:10.1002/cbic.200300677 (2003).
20 Florence, N. T. et al. Antidiabetic and antioxidant effects of Annona muricata (Annonaceae), aqueous extract on streptozotocin-induced diabetic rats. J Ethnopharmacol151, 784-790, doi:10.1016/j.jep.2013.09.021 (2014).
21 Dietrich, M. O. & Horvath, T. L. Hypothalamic control of energy balance: insights into the role of synaptic plasticity. Trends Neurosci36, 65-73, doi:10.1016/j.tins.2012.12.005 (2013).
22 Halaas, J. L. et al. Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci U S A94, 8878-8883, doi:10.1073/pnas.94.16.8878 (1997).
23 Considine, R. V. et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med334, 292-295, doi:10.1056/NEJM199602013340503 (1996).
24 Pospisilik, J. A. et al. Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell131, 476-491, doi:10.1016/j.cell.2007.08.047 (2007).
25 Shen, S. M. et al. Apoptosis-inducing factor is a target gene of C/EBPalpha and participates in adipocyte differentiation. FEBS Lett585, 2307-2312, doi:10.1016/j.febslet.2011.05.061 (2011).
26 Liu, C. X. et al. Adenanthin targets peroxiredoxin I and II to induce differentiation of leukemic cells. Nat Chem Biol8, 486-493, doi:10.1038/nchembio.935 (2012).
27 Gao, Y. H. et al. VHL deficiency augments anthracycline sensitivity of clear cell renal cell carcinomas by down-regulating ALDH2. Nat Commun8, 15337, doi:10.1038/ncomms15337 (2017).
28 Schenone, M., Dancik, V., Wagner, B. K. & Clemons, P. A. Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol9, 232-240, doi:10.1038/nchembio.1199 (2013).
29 Kotake, Y. et al. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol3, 570-575, doi:10.1038/nchembio.2007.16 (2007).
30 Liu, H. X. et al. A structure-activity guided strategy for fluorescent labeling of annonaceous acetogenin mimetics and their application in cell biology. Chembiochem8, 172-177, doi:10.1002/cbic.200600411 (2007).
31 Wienken, C. J., Baaske, P., Rothbauer, U., Braun, D. & Duhr, S. Protein-binding assays in biological liquids using microscale thermophoresis. Nat Commun1, 100, doi:10.1038/ncomms1093 (2010).
32 Geisler, J. G. 2,4 Dinitrophenol as Medicine. Cells8, doi:10.3390/cells8030280 (2019).
33 Tao, H., Zhang, Y., Zeng, X., Shulman, G. I. & Jin, S. Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice. Nat Med20, 1263-1269, doi:10.1038/nm.3699 (2014).
34 Kanemoto, N. et al. Antidiabetic and cardiovascular beneficial effects of a liver-localized mitochondrial uncoupler. Nat Commun10, 2172, doi:10.1038/s41467-019-09911-6 (2019).
35 Ishikawa, M., Tsuchiya, D., Oyama, T., Tsunaka, Y. & Morikawa, K. Structural basis for channelling mechanism of a fatty acid beta-oxidation multienzyme complex. EMBO J23, 2745-2754, doi:10.1038/sj.emboj.7600298 (2004).
36 Ibdah, J. A. et al. Lack of mitochondrial trifunctional protein in mice causes neonatal hypoglycemia and sudden death. J Clin Invest107, 1403-1409, doi:10.1172/JCI12590 (2001).
37 Yu, Y. et al. Subcellular proteome analysis of camptothecin analogue NSC606985-treated acute myeloid leukemic cells. J Proteome Res6, 3808-3818, doi:10.1021/pr0700100 (2007).
38 Morand, J. P., Macri, J. & Adeli, K. Proteomic profiling of hepatic endoplasmic reticulum-associated proteins in an animal model of insulin resistance and metabolic dyslipidemia. J Biol Chem280, 17626-17633, doi:10.1074/jbc.M413343200 (2005).
39 Klotz, A. V., Stegeman, J. J. & Walsh, C. An alternative 7-ethoxyresorufin O-deethylase activity assay: a continuous visible spectrophotometric method for measurement of cytochrome P-450 monooxygenase activity. Anal Biochem140, 138-145, doi:10.1016/0003-2697(84)90144-1 (1984).
40 Zhao, K. W. et al. Protein kinase Cdelta mediates retinoic acid and phorbol myristate acetate-induced phospholipid scramblase 1 gene expression: its role in leukemic cell differentiation. Blood104, 3731-3738, doi:10.1182/blood-2004-04-1630 (2004).